Chugai Completes Transfer of Rights to Maruho for Oxarol® Ointment 25μg/g and Oxarol® Lotion 25μg/g, Therapeutic Agents for Keratosis including Psoriasis Vulgaris, and Marduox® Ointment, a Therapeutic Agent for Psoriasis Vulgaris
TOKYO and OSAKA, December 2, 2019 -- Chugai Pharmaceutical Co., Ltd. (hereafter "Chugai") and Maruho Co., Ltd. (hereafter "Maruho") announced that in regard to the press release dated January 30, 2019, Chugai has completed the transfer of the relevant rights in Japan to Maruho as of December 1, 2019 for Oxarol® Ointment 25μg/g and Oxarol® Lotion 25μg/g, therapeutic agents for keratosis including psoriasis vulgaris, and Marduox® Ointment, a therapeutic agent for psoriasis vulgaris (hereafter "Products"). In Japan, Chugai obtained the manufacturing and marketing approval of the Products, and Maruho has been marketing the Products exclusively.
The Products are topical formulations containing active vitamin D3 derivative maxacalcitol as an active pharmaceutical ingredient, which was originated and is being manufactured by Chugai. The Products have been jointly developed by both companies since the launch of Oxarol® Ointment 25μg/g in 2001, and marketed exclusively by Maruho in Japan.
As of December 1, 2019, Maruho succeeded the manufacturing and marketing approval of the Products in Japan. Subsequently, Maruho retains the rights for research, development, manufacturing and marketing of the Products. Maruho continues to market and appropriately provide and collect relevant information for the Products, and will ensure stable supply.
As a pharmaceutical company specializing in dermatology, Maruho hopes to further contribute to patients suffering from psoriasis vulgaris through the succession of the relevant rights for the Products in Japan.
Chugai maintains the manufacturing and marketing approval rights in Japan and will continue to market Oxarol® Injection 2.5μg, 5μg, 10μg, therapeutic agents for secondary hyperparathyroidism.
The impact on the consolidated financials for the fiscal year ending December 2019 of Chugai is expected to be negligible.